standard care – Page 17 – Communicable Diseases Research

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

보행식 COVID-19에서 아지트로마이신 대 일반 치료의 다기관 공개 라벨 2군 무작위 우월성 임상 시험: ATOMIC2 시험을 위한 연구 프로토콜

Study Protocol

Published on 2020-08-172022-08-13
Journal: Trials [Category] MERS, 임상,

RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-07-292022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] age allocation concealment anticipated ARMS Blinding Care clinical clinically comparator Complete computer-generated conducted Continuous Continuous Positive Airway Pressure COVID-19 CPAP Critical care current death decision determine dissemination effective Effectiveness element eligible England Escalation exclusion criteria Face mask fraction Gender group-sequential HFNO High-flow nasal oxygen hospital Hospital stay include inclusion criteria Inpatient Intervention intubate intubation intubation rate invasive ventilation Ireland ISRCTN maintain mechanical ventilation Mortality mortality rate nasal nasal oxygen number objective Open-label outcome outcomes oxygen oxygen inhalation therapy Palliation parallel group participant Patient performed peripheral oxygen saturation plan positive airway pressure Pragmatic pressure Primary outcome protocol Public randomisation randomised randomised controlled randomised controlled trial Randomized receive recovery reported required researcher respiratory Respiratory failure risk Sample size secondary secondary outcome sequence Standard standard care standard oxygen therapy status Strategy stratified Study protocol System therapy tracheal Treatment Trial Version website Withdrawal
[DOI] 10.1186/s13063-020-04617-3 PMC 바로가기 [Article Type] Letter

Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-102022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Administered age antibiotic antiviral efficacy Asthma Azithromycin Beta blocker blinded block calcium cardiovascular change changed chronic clinical combination therapy Control control group coordinator COPD COVID-19 COVID-19 test Day days alive death derivative Diagnosis Direct Current discharged disorder dissemination double-blind study ECG element ergot alkaloid expected Final FiO2 generate Glucose glucose-6-phosphate dehydrogenase deficiency guide hearing loss hematological hospital hospitalisation Hospitalization hospitals Hydroxychloroquine hypersensitivity impede Inclusion Informed consent intensive care Interstitial lung disease Intervention intervention group invasive ventilation investigated investigator Liver disease lung maculopathy medication mental illness modulation myasthenia gravis negative pregnancy test network Neurogenic neurological number objective offered outcome parallel group participant Patient patients with COVID-19 Placebo pregnant Primary outcome problem protocol psoriasis pulmonary QTc QTc interval randomisation randomised randomised controlled trial receive recruited recruitment reduce Registered reported respiratory infections retinopathy risk Sample size sequence significantly Sponsor Standard standard care standard treatment status Stratification Study protocol the patient therapy treated Treatment Trial Visual field website women
[DOI] 10.1186/s13063-020-04409-9 PMC 바로가기 [Article Type] Letter

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 7-point ordinal scale accelerate activities activity acute respiratory syndrome adaptive addition administration Admission airway Akershus allocation sequence Analysis anticipated approach automatically baseline Biochemistry Biomarker blinded Blinding Blood C-reactive protein cardiac troponin Chloroquine clinical Clinical outcome Clinical practice clinical status clinical symptom collected condition coronavirus coronavirus disease COVID-19 Culture database Department disease dissemination early treatment element Endpoint examined excluded extracorporeal membrane oxygenation Good harmonization hepatic injury history hospital Hospital admission hospitalisation hospitalised hospitalised patient Hospitalized Hydroxychloroquine Hypothesis In-hospital include independent Inpatient intensive care intensive care unit International Conference Intervention intervention arm Invasive mechanical ventilation Laboratory marker Microbiology Mortality nasopharyngeal NEWS2 non-invasive ventilation Norway number Nurse objective open label Oropharyngeal Oropharyngeal sampling outcome oxygen participant Patient patients peptide Placebo polymerase chain polymerase chain reaction positive Practice Pragmatic pragmatic trial primary endpoint profile Prolonged Protein protocol QT interval randomisation randomised randomised controlled randomised controlled trial randomization Randomized Randomized controlled trial recruited recruitment Registered renal requiring supplemental oxygen resource responsible RT-PCR Safe Sample size SARS-CoV-2 SARS-CoV-2 viral load score secondary Seven standard care statistical analyses status Study protocol subjects Surveillance therapy transcriptase Treatment treatment allocation Trial Two-arm university use of hydroxychloroquine Viral load virological clearance viruses vital signs website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 A-a gradient acute lung injury acute respiratory distress addition allergic reaction alveolar macrophage alveolar pressure antiviral immunity Antwerp ARDS Belgium blinded Breastfeeding Bruges carbonate clinical clinician Confirmed COVID-19 infection control group Controlled trial COVID-19 COVID-19 pandemic defined Delta dissemination Effect element enrolled enrolment EudraCT ferritin level Ghent GM-CSF granulocyte-macrophage colony-stimulating factor High dose hospital Hypothesis hypoxic failure hypoxic respiratory failure Immune homeostasis inflammatory monocyte Inhaled Intervention intravenous invasive mechanical IWRS system leukine® lung malignancy mechanical ventilation mechanical ventilator Methylprednisolone number objective Open-label outcome oxygen Oxygenation paO2/fiO2 parameters Partial participant Participants Patient PF ratio pregnant primary endpoint progression of disease promote Protein protocol randomised randomised controlled trial randomization Randomized reached receive recruitment Registered Repair mechanisms replaced Respiratory failure Roeselare Sample size sargramostim SpO2 standard care Standard of care status Study protocol supplemental oxygen Support syndrome therapy treat Treatment Trial university ventilatory support Version website were excluded White blood cell
[DOI] 10.1186/s13063-020-04451-7 PMC 바로가기 [Article Type] Letter

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 95% confidence interval Adjusted analysis Administered Admission age alcohol allocation concealment ALT/AST Analysis Arm arrhythmia assigned Beta block-randomization Blood calculated Care center clinical Clinical improvement clinical trial conducted confirmed case control group cough COVID-19 COVID-19 confirmed patient COVID-19 in patient COVID-2019 Cox proportional-hazards model death discharge disease dissemination drug Duration education Effectiveness element eligibility enrolled excluded exclusion criteria fatigue follow-up time hazard headache Health hospital hospital discharge Hospitalization Hydroxychloroquine + Lopinavir/Ritonavir improvement include Interaction Interferon beta-1a Interferon-β 1a Interferon-β 1b intervals intervention group investigator Kaletra Kaplan–Meier laboratory result lactating women Last limit log-rank test Loghman Hakim Hospital Lopinavir Lopinavir/ritonavir masking mechanical ventilation Medical Science Medical Sciences moderate Mortality myalgia nasal NCT04343768 number objective open label Open-label Other outcome oxygen saturation package parallel group participant Patient performed positive pregnant Primary outcome primary outcome measure problem professional protocol pulse-oximetry R software R version 3.6.1 randomization randomization sequence Randomized Randomized controlled trial Randomly reached receive Recigen recruitment refusal regimen Registered Research respiratory rate RT-PCR test Sample SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale single center single dose SpO2 sputum production standard care status Study protocol Symptom temperature tested the patient therapeutic three groups time treat treated treatment groups Trial university version 3.6.1 website World Health Organization Ziferon
[DOI] 10.1186/s13063-020-04382-3 PMC 바로가기 [Article Type] Letter

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hour acute respiratory distress syndrome addition Administered Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor antibody Bacterial Belgium binding blinded blockade Blood characterized chest X-ray chimeric clinical Clinical improvement Combination composed Coronavirus infection COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient CT scan death defined discharge dissemination dose drug Effectiveness element EudraCT excluded experimental arm factorial design Fungal infection hospital hospital discharge Hospitalized hospitals hypoxia hypoxic respiratory failure ICU IL-1 IL-6 IL-6 blockade IL-6 receptor interleukin 1 blockade interleukin 6 blockade Intravenous injection Invasive mechanical ventilation LDH lymphopenia mechanical ventilation non-invasive ventilation number objective on mechanical ventilation open label Open-label outcome oxygen Oxygenation paO2/fiO2 participant Participants Patient patients with COVID-19 Phase 3 primary end point protocol randomisation randomised randomised controlled trial randomization Randomized receive receptor recruited recruitment Registered response Sample size Serum ferritin siltuximab standard care Standard of care status Study protocol subcutaneous injection supplemental oxygen syndrome System systemic cytokine systemic cytokine release syndrome Tocilizumab treated Trial usual care was selected Web website
[DOI] 10.1186/s13063-020-04453-5 PMC 바로가기 [Article Type] Letter

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

Review Article

Published on 2020-05-292022-10-04
Journal: Signal Transduction and Targeted Therapy [Category] MERS, SARS, 신약개발, 임상, 치료제,

[키워드] “cytokine storm” adaptive adaptive immune system approved biological processe cascade change chemokine Clinical management COVID-19 COVID-19 patients cytokine Cytokine storm Defense develop drugs dysregulation effective drug help highlight Host immune defense immune dysregulation immune response immune signaling pathway immune system immunopathology implicated Infectious diseases Inflammation Inflammatory innate response mechanism Mild molecular pathway pharmacological Prevent reflect SARS-CoV-2 SARS-COV-2 infection Severe case signaling pathway Spread stages standard care Supportive treatments systemic level therapeutic tissue damage treat Treatment triggered urgent investigation Vaccine viral infection virus virus entry widespread
[DOI] 10.1038/s41392-020-0191-1 PMC 바로가기 [Article Type] Review Article

Guideline-Based Chinese Herbal Medicine Treatment Plus Standard Care for Severe Coronavirus Disease 2019 (G-CHAMPS): Evidence From China

Medicine

Published on 2020-05-272022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial

경증/중등도의 COVID-19 성인 환자에 대한 로피나비르/리토나비르 또는 아르비돌의 효능 및 안전성: 탐색적 무작위 대조 시험

Randomized Controlled Trial

Published on 2020-05-192022-09-14
Journal: Med (New York, N.Y.) [Category] SARS, 임상, 진단, 치료제,

[키워드] adverse event affected antiviral medication approved Arbidol assigned benefit caused Characteristics Chest computed tomography clinical Clinical outcome clinical status clinician comparable Context control group Controlled Controlled trial coronavirus SARS-CoV-2 cough COVID-19 COVID-19 pandemic Deterioration drug effective Efficacy Efficacy and safety enrolled exploratory finding follow-up period funding global pandemic group Guangzhou HIV-1 IMPROVE Influenza Lopinavir/ritonavir Mild moderate Moderate COVID-19 monotherapy no difference novel coronavirus SARS-CoV-2 occurred pathogen Patient patients hospitalized primary endpoint Randomized Randomly receive Respiratory illness responsible Safety SARS-CoV-2 SARS-CoV-2 nucleic acid Scientific community Secondary endpoints Significance standard care supported supportive care tested the disease therapy three group Treatment university virus
[DOI] 10.1016/j.medj.2020.04.001 PMC 바로가기 [Article Type] Randomized Controlled Trial